Ahmed Halima
@AhmedHalimaMDRadiation Oncologist @GeisingerHealth through @ClevelandClinic
Similar User
@ShaunaRadOnc
@blally_md
@DrLouisCappelli
@ChrisFleming_MD
@betheladefres
@nataliezumab
@KWQuallsMD
@sarahkilicMD
@AmyLeMDMPH
@allisongardaMD
@DBuchbergerMD
@ajuloorimd
@snseyedinMD
@EbnerMD
@LeCompteMD
Unresectable HCC (median tumor diameter 10cm, 60% MVI) treated w IO+SBRT (N=63): -46% achieved complete response, much higher than prior trials of IO alone: atezo/bev (CR 5.5% IMBRAVE150) & STRIDE (3.3% CR) -CR associated w better OS (3yr 76% vs. 28%)! jamanetwork.com/journals/jamao…
Also found this to be a very notable finding from ADRIATIC & thought the same thing.
Improvements in radiation using IMRT translated into less pneumonitis for locally-advanced NSCLC in NRG Oncology-RTOG 0617 compared to 3D-CRT. Planning should minimize the heart V40Gy and lung V20Gy, as the lung V5Gy had no long-term impact on outcome. ja.ma/3XvFTN7
#ESMO24 Lung mini-orals🔥 Randomised ph II trial of inhaled corticosteroids in stage III NSCLC treated with cCRT, to reduce radiation pneumonitis: - 292pts - 15% reduction in RP - no long-term steroid tox No need for ph III, could do tomorrow #ESMOAmbassadors #ESMO24 @myESMO
Major congrats to my friend Dr Sofia Rivera on the HypoG-01 just presented at #ESMO2024 Hypofractionation not inferior to conventional fractionation for #BreastCancer with nodal RT. ✅Similar toxicity ✅Similar efficacy (BCSM OS LRFS DMFS) 3 weeks is the way to go!
All well that ends with OS. HR of 0.67 for Pembrolizumab in Keynote A18 What about Interlace approach? KeynoteA18 vs Interlace or Both ? Interlace not yet published since last esmo23 presentation ?? @BanerjeeSusana @5_utr @barriere_dr @Larvol @OncoAlert #ESMO24
So what's the story for day 2 of Esmo24 ? Keynote A18 shows OS benifit. Pembrolizumab in CTRT for cervix. HR 0.67 ( 0.5 to 0.90 ) 82.6 % vs 74.8 % OS at 36 months . OS Benifit seen across all the stages . This should make it new SOC. 🙂👍@esmo #ESMO2024 @Larvol @OncoAlert…
This is a big deal. Cancer #cachexia is terrible and significantly impacts quality of life for patients.
🚨🚨Hot off the press @NEJM In a randomized Ph II Ponsegromab, an anti-GDF15 mAB, increased weight gain, overall physical activity and reduced cachexia symptoms in patients with #cachexia and ⬆️ GDF-15 nejm.org/doi/full/10.10…
So what's the story for day 2 of Esmo24 ? Keynote A18 shows OS benifit. Pembrolizumab in CTRT for cervix. HR 0.67 ( 0.5 to 0.90 ) 82.6 % vs 74.8 % OS at 36 months . OS Benifit seen across all the stages . This should make it new SOC. 🙂👍@esmo #ESMO2024 @Larvol @OncoAlert…
And so it begins. This is required reading for all brain tumor docs. Vorasidenib: a new hope or a false promise for patients with low-grade glioma? | Nature Reviews Clinical Oncology nature.com/articles/s4157…
What a huge impact @DrOmarMian made on all of us here - can’t wait to see your continued success
Grateful for 8 wonderful years at the @ClevelandClinic @CCLRI I will miss my amazing colleagues. So excited for the next adventure at @fredhutch @uwradonc!
Single fraction RT (8Gy) significantly improves hepatic pain compared with best supportive care and can be considered standard palliative treatment. No increase in toxicity. @ldawsonmd @CDNCancerTrials thelancet.com/journals/lanon…
Single fraction lung SBRT has become my go-to for medically inoperable stage I NSCLC. How about others? #radonc pubmed.ncbi.nlm.nih.gov/34048817/
The more gains you seek, the more losses will inadvertently occur along the way. Being so fixated on accomplishing the pre-set goals might make you unaware of the losses that aren't always directly related to the goal.
New radiotracer for clear cell renal carcinoma - CA-9 targeting peptide: SUVs >100 in tumor in first 3 patients with low background activity = WOW !! jnm.snmjournals.org/content/early/… @DebiopharmNews @DrBenTran @JournalofNucMed @PeterMacRes
malaria vaccine. Malaria vaccine WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization 75% reduction in malaria
Bone Met week 3/5 Post-op RT after surgical stabilization long bones, should you treat entire hardware? YES doi.org/10.1016/j.adro…
I am excited to share our paper in @AnnSurgOncol on updated outcomes of IORT in Early stage breast cancer. @CShahMD @SeanParkerMD
PUBLISHED: #IntraoperativeRadiationTherapy for #EarlyStageBreastCancer: Updated Outcomes from a Single-Institution Experience. rdcu.be/dpid4 @SocSurgOnc
Another prospective study published in October 2023 in JTO shows similar cancer specific survival and OS when SBRT/SABR cohort matched with surgical cohort in pts with T<2 cm, N0,M0 NSCLC. Both cohorts achieved 88-90% lung ca specific survival at 10 years.
United States Trends
- 1. Bengals 80,9 B posts
- 2. Chargers 70,5 B posts
- 3. McPherson 12,4 B posts
- 4. Herbert 35,8 B posts
- 5. Joe Burrow 22,1 B posts
- 6. #BaddiesMidwest 22,2 B posts
- 7. #BoltUp 5.699 posts
- 8. Zac Taylor 4.443 posts
- 9. #ช็อตฟีลMV 177 B posts
- 10. MILKLOVE SHOT FEEL 229 B posts
- 11. #CINvsLAC 10,6 B posts
- 12. WWIII 184 B posts
- 13. #MondayMotivation 9.241 posts
- 14. 60 Minutes 33,9 B posts
- 15. Dobbins 8.818 posts
- 16. TAEYEON 38,8 B posts
- 17. Scotty 10,3 B posts
- 18. Carti 17,1 B posts
- 19. Ladd McConkey 2.667 posts
- 20. Harbaugh 16,5 B posts
Who to follow
-
Shauna Campbell, DO
@ShaunaRadOnc -
Brian Lally, MD
@blally_md -
LouisCappelli
@DrLouisCappelli -
Chris Fleming
@ChrisFleming_MD -
Bethel Adefres
@betheladefres -
Natalie Ridge, DO, MS (she/her)
@nataliezumab -
Kaitlin Qualls, MD
@KWQuallsMD -
Sarah Kilic, MD
@sarahkilicMD -
Amy Le
@AmyLeMDMPH -
Allison Garda
@allisongardaMD -
David Buchberger
@DBuchbergerMD -
Aditya Juloori
@ajuloorimd -
Steven Seyedin
@snseyedinMD -
Dan Ebner
@EbnerMD -
Michael LeCompte
@LeCompteMD
Something went wrong.
Something went wrong.